Prescriptions for direct-acting antivirals (DAAs) to treat hepatitis C have fallen by nearly two-thirds over the past decade since their introduction in 2013. This significant decline indicates that there is an unmet need for the treatment of hepatitis C virus infections. This is a significant trend that points to problems in the availability or use of these treatment options, according to an article in MedPage Today. Although antiviral drugs are an effective treatment for HCV, declining prescriptions indicate that patients do not have sufficient access to these drugs or that there are other barriers to their use. These developments highlight the need to address the barriers that prevent patients from obtaining effective hepatitis C treatment.